Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of ...
MyChesCo on MSN
FDA push to replace animal testing signals major shift
WASHINGTON, D.C. — Federal regulators are moving to reduce the use of animal testing in drug development, issuing new ...
FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
March 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday issued a draft guidance to help companies reduce ...
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...
The guidance clarifies what sponsors should consider when putting together an application for the validation of a NAM ...
Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...
The FDA has released draft guidance aimed at helping drug developers shift away from traditional animal testing as the ...
In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from ...
The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t ...
As regulatory authorities accelerate the use of New Approach Methodologies (NAMs), the drug discovery landscape is changing dramatically. This webinar explores how NAMs, immunology-driven platforms, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results